Escitalopram in Schizophrenia in OCD- Open Label Study

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Beer Yaakov MHC

Beer Yaakov, 70350, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who suffer from schizophrenia and OCD

Exclusion criteria

Substance abuse,
Serious medical condintions,
Being on SSRI treatment

Treatment and study plan

Escitalopram

Drug

Sponsors and collaborators

Lead sponsor

BeerYaakov Mental Health Center

Other Gov

Collaborators

Lundbeck Israel

Registry information

Official study title

Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2008
First posted: Apr 5, 2007
Registry last updated: Jan 27, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed